How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? – Estimates form a large single center-Reference-Cited by-同舟云学术

How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? – Estimates form a large single center

Published:2017-11 Issue: Volume:30 Page:28-32
ISSN:1567-5688
Container-title:Atherosclerosis Supplements
language:en
Short-container-title:Atherosclerosis Supplements

Author:

Hohenstein Bernd,Tselmin Sergey,Bornstein Stefan R.,Julius Ulrich

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,General Medicine,Internal Medicine

Reference16 articles.

1. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: findings gathered from more than 36,000 treatments at one center in Germany;Heigl;Atheroscler Suppl,2015

2. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study;Leebmann;Circulation,2013

3. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern;von Dryander;Atheroscler Suppl,2013

4. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

5. Actual situation of lipoprotein apheresis in Saxony in 2013;Emmrich;Atheroscler Suppl,2015

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management and clinical outcomes of patients with homozygous familial hypercholesteremia in Saudi Arabia;Monaldi Archives for Chest Disease;2023-02-02

2. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study;Journal of Cardiovascular Pharmacology and Therapeutics;2020-07-30

3. Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis;Atherosclerosis Supplements;2019-12

4. Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study;Journal of Clinical Lipidology;2019-11

5. Inhibidores de la PCSK9: una nueva mejora para la salud;Clínica e Investigación en Arteriosclerosis;2019-09